Characteristic and Mechanism of Drug-Herb Interaction Between Acetylsalicylic Acid and Danhong Injection Mediated by Organic Anion Transporters

The mixture of Salvia miltiorrhiza and Carthamus tinctorius (Danhong injection, DHI) is widely prescribed in China for the treatment of cardiovascular and cerebrovascular diseases. In most cases, DHI is used in combination with acetylsalicylic acid (aspirin, ASA). However, the interaction between DH...

Full description

Saved in:
Bibliographic Details
Main Authors: Jianping Li (Author), Jingbo Lu (Author), Yin Peng (Author), Xuejun Xu (Author), Chenkai Chen (Author), Ming Gao (Author), Ling Lin (Author), Jianming Guo (Author), Jinao Duan (Author)
Format: Book
Published: Frontiers Media S.A., 2020-10-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_0a411a9b03724b10acbcc9740a928e13
042 |a dc 
100 1 0 |a Jianping Li  |e author 
700 1 0 |a Jianping Li  |e author 
700 1 0 |a Jingbo Lu  |e author 
700 1 0 |a Jingbo Lu  |e author 
700 1 0 |a Yin Peng  |e author 
700 1 0 |a Yin Peng  |e author 
700 1 0 |a Xuejun Xu  |e author 
700 1 0 |a Xuejun Xu  |e author 
700 1 0 |a Chenkai Chen  |e author 
700 1 0 |a Chenkai Chen  |e author 
700 1 0 |a Ming Gao  |e author 
700 1 0 |a Ling Lin  |e author 
700 1 0 |a Jianming Guo  |e author 
700 1 0 |a Jianming Guo  |e author 
700 1 0 |a Jinao Duan  |e author 
700 1 0 |a Jinao Duan  |e author 
245 0 0 |a Characteristic and Mechanism of Drug-Herb Interaction Between Acetylsalicylic Acid and Danhong Injection Mediated by Organic Anion Transporters 
260 |b Frontiers Media S.A.,   |c 2020-10-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2020.577012 
520 |a The mixture of Salvia miltiorrhiza and Carthamus tinctorius (Danhong injection, DHI) is widely prescribed in China for the treatment of cardiovascular and cerebrovascular diseases. In most cases, DHI is used in combination with acetylsalicylic acid (aspirin, ASA). However, the interaction between DHI and ASA remains largely undefined. The purpose of this study is to explore the interaction profile and mechanism between DHI and ASA. The frequency of drug combination of DHI and ASA was analyzed based on 5,183 clinical cases. The interaction characteristics were evaluated by analyzing the pharmacokinetics and disposition profile of salicylic acid (SA, the primary metabolite of ASA) in rats. The interaction mechanisms were explored through evaluating the hydrolysis of ASA regulated by ASA esterase, the tubular secretion of SA mediated by influx and efflux transporters, and the tubular reabsorption of SA regulated by urinary acidity-alkalinity. The inhibitory potential of DHI on organic anion transporters (OATs) was further verified in aristolochic acid I (AAI) induced nephropathy. Clinical cases analysis showed that DHI and ASA were used in combination with high frequency of 70.73%. In drug combination of DHI and ASA, the maximum plasma concentration of SA was significantly increased by 1.37 times, while the renal excretion of SA was significantly decreased by 32.54%. The mechanism study showed that DHI significantly inhibited the transport function, gene transcription and protein expression of OATs. In OATs mediated AAI nephropathy, DHI significantly reduced the renal accumulation of AAI by 55.27%, and alleviated renal damage such as glomerulus swelling, tubular blockage and lymphocyte filtration. In drug combination of DHI and ASA, DHI increased the plasma concentration of SA not through enhancing the hydrolysis of ASA, and the tubular reabsorption of SA was not significantly affected. Inhibition of tubular secretion of SA mediated by OATs might be the reason that contributes to the decrease of SA renal excretion. 
546 |a EN 
690 |a organic anion transporter 
690 |a drug interaction 
690 |a acetylsalicylic acid (aspirin) 
690 |a Danhong injection 
690 |a salicylic acid 
690 |a aristolochic acid 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 11 (2020) 
787 0 |n https://www.frontiersin.org/article/10.3389/fphar.2020.577012/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/0a411a9b03724b10acbcc9740a928e13  |z Connect to this object online.